Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18632851 | 0.93 | KMT2A (0.32) | LMNAPOLBALDH1A1KMT2AALOX12 | |
| SCHEMBL329518 | 0.87 | KMT2A (0.38) | LMNAPOLBALDH1A1KMT2AALOX12 | |
| SCHEMBL2625534 | 0.87 | KMT2A (0.37) | LMNAPOLBALDH1A1KMT2AALOX12 | |
| SCHEMBL2625532 | 0.87 | KMT2A (0.37) | LMNAPOLBALDH1A1KMT2AALOX12 | |
| SCHEMBL2622404 | 0.87 | KMT2A (0.37) | LMNAPOLBALDH1A1KMT2AALOX12 | |
| SCHEMBL19367719 | 0.84 | KMT2A (0.31) | LMNAPOLBALDH1A1KMT2AALOX12 | |
| SCHEMBL21401232 | 0.82 | — | — | |
| SCHEMBL6985391 | 0.81 | KMT2A (0.33) | LMNAPOLBALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL18632852 | 0.80 | — | — | |
| SCHEMBL19441508 | 0.77 | PKM (0.36) | LMNAPOLBALDH1A1KMT2AALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | EZH2, BMI1, EZH1 | LMNA 3180/4885POLB 3049/4885ALDH1A1 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.